Amphista Therapeutics is a UK-based biopharmaceutical company creating first-in-class therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins.

The company’s next generation targeted protein degradation (TPD)-based medicines use a novel set of mechanisms that make use of a wider range of the body’s own innate protein degrading proteins, instead of the very narrow set of ubiquitin E3 ligase-based mechanisms used by most other TPD companies. This proprietary approach offers the potential to overcome many of the limitations seen with current TPD approaches, providing the opportunity to treat a wider range of diseases, including cancer.

Amphista Therapeutics raised a $53 million (£38 million) Series B financing co-led by Gilde Healthcare to further develop its differentiated TPD platform and bring drug candidates to the clinic.